[Ip-health] Infojustice Roundup - January 20, 2015

Michael Palmedo mpalmedo at wcl.american.edu
Tue Jan 20 10:37:23 PST 2015

Infojustice Roundup 


Announcing the Institutional Partner for the Global Congress on Intellectual Property and the Public Interest 2015


[Nehaa Chaudhari] As you might know, the Centre for Internet and Society, India will be hosting the 4th Global Congress on Intellectual Property and the Public Interest at New Delhi, India. We're pleased to welcome on board National Law University, New Delhi ("NLU-D"), as our Institutional Partner.  NLU-D will be the venue for the Congress, later this year. Click here for more. <http://infojustice.org/archives/33778> 




USTR Request for Public Comment and Announcement of Public Hearing for the 2015 Special 301 Review


[Federal Register Notice] ... USTR is hereby requesting written submissions from the public concerning foreign countries that deny adequate and effective protection of intellectual property rights or deny fair and equitable market access to U.S. persons who rely on intellectual property protection. Click here for more. <http://infojustice.org/archives/33765> 


AJIC Journal Call for Articles: "African Intersections between IP Rights and Knowledge Access"


The African Journal of Information and Communication (AJIC), an accredited, peer-reviewed journal published by the LINK Centre at Wits University in Johannesburg, is calling for submissions to its 2015 Thematic Issue to be entitled "African Intersections between IP Rights and Knowledge Access". Submissions, to Guest Editor Chris Armstrong, are due on or before 30 April 2015. Go to the Call for Submissions <http://www.wits.ac.za/files/v35ck_279802001421406295.pdf> .


Gilead Denied Patent for Hepatitis C Drug Sofosbuvir in India


[Médecins Sans Frontières] The Indian Patent Controller has today rejected one of Gilead's key patent applications which covered the drug sofosbuvir, used to treat hepatitis C (HCV). The oral drug, which first received regulatory approval in the US in November 2013, and has been priced by Gilead at US$84,000 for a treatment course, or $1,000 per pill in the US, has caused a worldwide debate on the pricing of patented medicines. A study from Liverpool University showed that sofosbuvir could be produced for as little as $101 for a three-month treatment course. Click here for more. <http://infojustice.org/archives/33770> 


See Also:  Swaraj Paul Barooah, Spicy IP. Gilead to Appeal Sofosbuvir Patent Rejection.  Link. <http://spicyip.com/2015/01/gilead-to-appeal-sofosbuvir-patent-rejection.html> 




AU School of International Service Conference: Convergence and Divergence in Mega-Bilateral Trade and Investment Agreements


[PIJIP] This conference will explore the new challenges posed by bilateral trade and investment treaties such as TPP, CETA, and TTIP, against the background of the multilateral trade regime. Do these treaties replace or complement multilateralism in the WTO framework? The first panel will offer an overview of the various trade agreements, their possible convergence, and different geopolitical implications. The second panel will focus on key critical and controversial issues by addressing sectors such as IP, investment, and data privacy. The conference is a joint project of the AU School of International Service, and the AU Washington College of Law Program on International Organizations, Law, and Diplomacy. Click here for more. <http://infojustice.org/archives/33759>  





More information about the Ip-health mailing list